Half life: 18-32 days infusion rxn Pregnancy status, and PD: binds to and/or mucocutaneous birth control measures CD20 rxn. during tx and 12 months surface antigens Hep B reactivation after Caution if malignancy risk Hold if active infection BIOLOGICS TNF alpha Inhibitors DRUG/PK/PD TOXICITIES / SE TO BASELINE ROS/EXAM LABORATORY / MONITOR MONITORING MONITORING Infliximab S/S of immune Hep B & C screen, TB S/S of infection or CBC Enteracept suppression screen, immunization malignancy Preg Cat.B Adalimumab S/S of melanoma status. Increased risk for Golimumab Worsening CHF lymphoma and Certolizumab pergol Hold if active infection melanoma DOSE: Varies by drug CHF and route Drug induced lupus PK: CYP450:none PD: inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response.
Half life: 18-32 days PD: binds to CD20 surface antigens infusion rxn and/or mucocutaneous rxn. Hep B reactivation Caution if malignancy risk Hold if active infection Pregnancy status, and birth control measures during tx and 12 months after BIOLOGICS TNF alpha Inhibitors DRUG/PK/PD TOXICITIES / SE TO MONITOR BASELINE MONITORING ROS/EXAM LABORATORY / MONITORING Infliximab Enteracept Adalimumab Golimumab Certolizumab pergol DOSE: Varies by drug and route PK: CYP450:none PD: inhibits tumor necrosis factor alpha, reducing inflammation and altering immune response. S/S of immune suppression S/S of melanoma Worsening CHF Hold if active infection Hep B & C screen, TB screen, immunization status. S/S of infection or malignancy Increased risk for lymphoma and melanoma CHF Drug induced lupus CBC Preg Cat.B
Appendix%201-AutoImmune%20drug%20list.docx